Latest Information Update: 04 Oct 1995
At a glance
- Originator Bayer Schering Pharma
- Class Contrast media; Organometallic compounds; Polyamines
- Mechanism of Action Magnetic resonance imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 04 Oct 1995 Discontinued - Preclinical for Undefined in Germany (unspecified route)